Ribavirin Analogs

Clinics in Liver Disease

Volumn 13, Issue 3, 2009, Pages 419-427

  Shields, William W ^a   Pockros, Paul J ^b  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Anemia; Hepatitis C virus; Pegylated interferon; Ribavirin; Taribavirin

Indexed keywords

ALPHA INTERFERON; INTERFERON; LEVOVIRIN; MERIMEPODIB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RIBAVIRIN DERIVATIVE; TARIBAVIRIN;

ANEMIA; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; NAUSEA; NONHUMAN; REVIEW; TREATMENT RESPONSE; VIRUS INFECTION;

ANEMIA, HEMOLYTIC; ANTIVIRAL AGENTS; CARBAMATES; HEPACIVIRUS; HEPATITIS C; HUMANS; IMP DEHYDROGENASE; MYCOPHENOLIC ACID; PHENYLUREA COMPOUNDS; RIBAVIRIN;

EID: 67650641166     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2009.05.006     Document Type: Review

References (43)

1. The Department of Health and Human Services Center for Disease Control and Prevention. Hepatitis C. Available at:. http://www.cdc.gov/hepatitis/HCV.htm Accessed October 9, 2008
2. National Institutes of Health. Consensus Development Conference Statement: management of hepatitis C. Hepatology 36 5 Suppl. 1 (2002) S3-20
3. Thevenot T., Regimbeau C., Ratziu V., et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naïve patients: 1999 update. J Viral Hepat 8 1 (2001) 48-62
4. Carithers Jr. R.L., and Emerson S.S. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 26 3 Suppl. 1 (1997) 83S-88S
5. Di Bisceglie A., Conjeevaram H.S., Fried M.W., et al. Ribavirin as therapy of chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 123 12 (1995) 897-903
6. Reichard O., Norkrans G., Frydén A., et al. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 351 (1998) 83-87
7. McHutchison J.G., Gordon S.C., Schiff E.R., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C Hepatitis Interventional Therapy Group. N Engl J Med 339 21 (1998) 1485-1492
8. Hadziyannis S.J., Sette H., Morgan T.R., et al. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 5 (2004) 346-355
9. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection. N Engl J Med 347 13 (2002) 975-982
10. Reddy K.R., Shiffman M.L., Morgan T.R., et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 5 1 (2007) 124-129
11. Witkowski J.T., Robins R.K., Sidwell R., et al. Design, synthesis, and broad spectrum antiviral activity of 1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem 15 11 (1972) 1150-1154
12. Copegus (ribavirin, USP) [package insert]. Roche Laboratories Inc, Nutley, New Jersey. 2004.
13. Wu J.Z., Larson G., Walker H., et al. Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: implications for ribavirin metabolism in erythrocytes. Antimicrob Agents Chemother 49 6 (2005) 2164-2171
14. Lau J.Y., Tam R.C., Liang T.J., et al. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35 5 (2002) 1002-1009
15. Wu J.Z., Walker H., Lau J.Y., et al. Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob Agents Chemother 47 1 (2003) 426-431
16. Shiina M., Kobayashi K., Satoh H., et al. Ribavirin upregulates interleukin-12 receptor and induces T-cell differentiation towards type 1 in chronic hepatitis C. J Gastroenterol Hepatol 19 (2004) 558-564
17. Tam R.C., Pai B., Bard J., et al. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J Hepatol 30 3 (1999) 376-382
18. Crotty S., Maag D., Arnold J.J., et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 6 12 (2000) 1375-1379
19. Homma M., Matsuzaki Y., Inoue Y., et al. Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin Gastroenterol Hepatol 2 4 (2004) 337-339
20. De Franceschi L., Fattovich G., Turrini F., et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidation damage. Hepatology 31 4 (2000) 997-1004
21. Pockros P.J., and Balart L.A. Advances in hepatology research. Rev Gastroenterol Disord 8 3 (2008) 194-212
22. Zeuzem S., Hezode C., Ferenci P., et al. Telaprevir in combination with peginterferon alfa-2a with or without ribavirin in the treatment of chronic hepatitis C: final results of the PROVE 2 study. [abstract]. Hepatology 48 Suppl (2008) 418A
23. Pockros P.J., Nelson D., Godofsky E., et al. R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 48 2 (2008) 385-397
24. Kwo P., Lawitz E.J., McCone J., et al. HCV SPRINT-1: bocepravir plus peginterferon alfa-2b/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients. [abstract]. Hepatology 48 Suppl (2008) 1027A
25. Lin C.-C., Yeh L.T., Vitarella D., et al. Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. Antivir Chem Chemother 14 3 (2003) 145-152
26. Wu J.Z., Larson G., and Hong Z. Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin. Antimicrob Agents Chemother 48 10 (2004) 4006-4008
27. Lin C.-C., Philips L., and Xu C. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin in healthy volunteers. J Clin Pharmacol 44 3 (2004) 265-275
28. Gish R.G., Arora S., Rajender Reddy K., et al. Virological response and safety outcomes in therapy-naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized phase 2 study. J Hepatol 47 1 (2007) 51-59
29. Behamou Y., Pockros P., Rodriguez-Torres M., et al. The safety and efficacy of viramidine plus PegIFN alfa-2b versus ribavirin plus PegIFN alfa-2b in therapy-naïve patients infected with hepatitis C virus: phase 3 results (VISER 1). [abstract]. J Hepatol 44 (2006) 273A
30. Marcellin P., Lurie Y., Rodriguez-Torres M., et al. The safety and efficacy of taribavirin plus pegylated interferon alfa-2a versus ribavirin plus pegylated interferon alfa-2a in therapy-naïve patients infected with hepatitis C virus: phase 3 results. [abstract]. J Hepatol 46 (2007) 7A
31. Pockros P.J., Jacobson I.M., Bacon B.R., et al. Taribavirin exposure analysis from a previous phase 3 trial correlates with phase 2B weight-based dosing interim results. [abstract]. Hepatology 48 Suppl (2008) 1138A
32. Lawitz E., Muir A., Poordad F., et al. Treatment week 24 results of weight-based taribavirin versus weight-based ribavirin both with peginterferon alfa-2b in naïve chronic hepatitis C, genotype 1 patients. [abstract]. Hepatology 48 Suppl (2008) 433A
33. Valeant pharmaceutical international, media center, new release. Available at:. www.valeant.com Accessed December 19, 2008
34. Tam R.C., Ramassamy K., Bard J., et al. The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels. Antimicrob Agents Chemother 44 5 (2000) 1276-1283
35. Lin C.-C., Luu T., Lourenco D., et al. Absorption, pharmacokinetics and excretion of levovirin in rats, dogs, and cynomolgus monkeys. J Antimicrob Chemother 51 (2003) 93-99
36. Pockros P., Pessoa M., Diago M., et al. Combination of levovirin and pegylated interferon α-2a fails to generate an induction response comparable to ribavirin and pegylated interferon α-2a in patients with CHC. [abstract]. Antivir Ther 9 (2004) H17 A32
37. Markland W., McQuaid T.J., Jain J., et al. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother 44 4 (2000) 859-866
38. McHutchison J.G., Shiffman M.L., Cheung R.C., et al. A randomized, double-blind, placebo-controlled dose escalation trial of merimepodib (VX-497) and interferon alpha in previous untreated patients with chronic hepatitis C. Antivir Ther 10 5 (2005) 635-643
39. Marcellin P., Horsmans Y., Nevens F., et al. Phase 2 study of the combination of merimepodib with peginterferon alpha-2b and ribavirin in nonresponders to previous therapy for chronic hepatitis C. J Hepatol 47 4 (2007) 476-483
40. Hezode C., Bouvier-Aliasi M., Costentini C., et al. Effect of IMPDH inhibition, Merimepobid (MMPD), assessed in combination with ribavirin (RBV), and alone, on HCV replication: implications regarding RBV's mechanism of action. [abstract]. Hepatology 44 4 Suppl 1 (2006) 615A
41. Cornberg M., Hinrichsen H., Teuber G., et al. Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon nonresponder patients with chronic hepatitis C. J Hepatol 37 6 (2002) 843-847
42. Henry S.D., Metselaar H.J., Lonsdale R.C., et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporine A and interferon alpha. Gastroenterology 131 5 (2006) 1452-1462
43. Ramos-Casals M., and Font J. Mycophenolate mofetil in patients with hepatitis C virus infection. Lupus 14 Suppl 1 (2005) S64-S72